Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal Testosterone for HSDD in Menopausal Women on Estrogen
NCT00384046Phase 3Completed
- Sponsor
- Warner Chilcott
- Start
- Nov 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of Testosterone TEPI patch in hypoactive sexual desire disorder (HSDD) (2 arms), sponsored by Warner Chilcott. Primary endpoint: Frequency of total satisfying episodes at 24 weeks. Started Nov 2006; status: completed.
02
Drugs
Testosterone TEPI patch
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT00384046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384046.